RxDoctor Payments Data

Laura Dohm, PA

Medical · Bethlehem, PANPI 1013345289

Payments from drug & device makers

$1,558in general payments, 2019–2025

Across 26 payments — averaging $59.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$654
  • E.r. Squibb & Sons, L.L.C.$291
  • Boehringer Ingelheim$223
  • Scpharmaceuticals Inc.$152
  • Lexicon Pharmaceuticals, Inc.$125
  • Novartis$52
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$1,558100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,558 in reported general payments places this provider in the 75th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$61,987
Medicare patients
431
Services billed
839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$166,643
EntrestoSacubitril/Valsartan62$65,744
XareltoRivaroxaban33$39,218
FarxigaDapagliflozin Propanediol12$14,312
JardianceEmpagliflozin18$14,061
Praluent PenAlirocumab16$7,698
Metoprolol Succinate198$4,251
Torsemide142$3,445
Atorvastatin Calcium168$2,133
Potassium Chloride93$1,405
Valsartan40$1,260
Losartan Potassium92$1,067
Rosuvastatin Calcium82$984
Furosemide191$981
Spironolactone126$901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$52$65,74462 claims
Boehringer IngelheimJardiance$223$14,06118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →